FACTORS ASSOCIATED WITH PERSISTENCE OF GOLIMUMAB TREATMENT IN THE BIOBADASER REGISTRY, UP TO 7 YEARS OF FOLLOW-UP

Simple item page
dc.conference.dateJUN 03, 2020
dc.conference.titleAnnual European Congress of Rheumatology (EULAR)
dc.contributor.authorPombo, M.
dc.contributor.authorSanchez-Piedra, C.
dc.contributor.authorCea-Calvo, L.
dc.contributor.authorManrique Arija, S.
dc.contributor.authorGarcia-Magallon, B.
dc.contributor.authorCampos Fernandez, C.
dc.contributor.authorNotario, I.
dc.contributor.authorDiaz-Gonzalez, F.
dc.contributor.authorGomez-Reino, J. J.
dc.contributor.authoraffiliation[Pombo, M.] HCU Santiago de Compostela, Santiago De Compostela, Spain
dc.contributor.authoraffiliation[Gomez-Reino, J. J.] HCU Santiago de Compostela, Santiago De Compostela, Spain
dc.contributor.authoraffiliation[Sanchez-Piedra, C.] Soc Espanola Reumatol, Madrid, Spain
dc.contributor.authoraffiliation[Cea-Calvo, L.] MSD Spain, Med Affairs Dept, Madrid, Spain
dc.contributor.authoraffiliation[Manrique Arija, S.] H Reg U Malaga, IBIMA, UGC Reumatol, Malaga, Spain
dc.contributor.authoraffiliation[Garcia-Magallon, B.] HG San Jorge, Huesca, Spain
dc.contributor.authoraffiliation[Campos Fernandez, C.] HGU Valencia, Valencia, Spain
dc.contributor.authoraffiliation[Notario, I.] HU Virgen Nieves, Granada, Spain
dc.contributor.authoraffiliation[Diaz-Gonzalez, F.] HU Canarias, Tenerife, Spain
dc.contributor.funderSpanish Society of Rheumatology (SER) - MSD Spain
dc.date.accessioned2025-01-07T14:22:38Z
dc.date.available2025-01-07T14:22:38Z
dc.date.issued2020-06-01
dc.identifier.doi10.1136/annrheumdis-2020-eular.3490
dc.identifier.essn1468-2060
dc.identifier.issn0003-4967
dc.identifier.unpaywallURLhttps://ard.bmj.com/content/annrheumdis/79/Suppl_1/733.2.full.pdf
dc.identifier.urihttps://hdl.handle.net/10668/26332
dc.identifier.wosID555905002254
dc.issue.number1
dc.journal.titleAnnals of the rheumatic diseases
dc.journal.titleabbreviationAnn. rheum. dis.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de las Nieves
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.number729-730
dc.publisherBmj publishing group
dc.rights.accessRightsopen access
dc.titleFACTORS ASSOCIATED WITH PERSISTENCE OF GOLIMUMAB TREATMENT IN THE BIOBADASER REGISTRY, UP TO 7 YEARS OF FOLLOW-UP
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number79
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de las Nieves
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía